The goal of this clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain. The main questions it aims to answer are:

- Do bromfenac sodium and/or loteprednol etabonate improve post-injection pain scores compared to preservative-free artificial tears?

Participants will:

• Receive one drop of the topical drops five minutes prior to their regularly scheduled intravitreal injection. Depending on the treatment arm, they will also administer drops on their own at home up to 3 times per day on the day of their procedure.
• They will answer a standardized pain score survey at 4 hours and 24 hours following their intravitreal injection and convey their results to study coordinators by phone.

Inclusion Criteria:

• Standard of Care Treatment with intravitreal injection
• History of at least 1 anti-VEGF injection in the 90 days prior to inclusion
• Less than 13 intravitreal injection in the 365 days prior to inclusion

Exclusion Criteria:

• History of autoimmune disease, graft versus host disease, neurotrophic corneal disease, contact lens use, keratitis, fibromyalgia, uveitis, herpetic ocular disease
• Drug allergy to any drug components
• History of any ocular surgery in the 30 days prior to inclusion
• Current topical corticosteroid or non-steroidal anti-inflammatory drug (NSAID)

All IPD Collected throughout the trial